Ourania Tatsis - 10 Feb 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
10 Feb 2022
Net transactions value
-$360,595
Form type
4
Filing time
14 Feb 2022, 15:22:42 UTC
Previous filing
03 Feb 2022
Next filing
22 Feb 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $292,420 -1,230 -2.1% $237.74 58,027 10 Feb 2022 Direct
transaction VRTX Common Stock Sale $23,392 -100 -0.17% $233.92 57,927 11 Feb 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale $18,325 -78 -0.13% $234.93 57,849 11 Feb 2022 Direct F1, F3, F4
transaction VRTX Common Stock Sale $16,511 -70 -0.12% $235.87 57,779 11 Feb 2022 Direct F1, F3, F5
transaction VRTX Common Stock Sale $9,948 -42 -0.07% $236.85 57,737 11 Feb 2022 Direct F1, F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $233.92 (range $233.26 to $234.24).
F3 Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $234.93 (range $234.28 to $235.25).
F5 Open market sales reported on this line occurred at a weighted average price of $235.87 (range $235.41 to $236.08).
F6 Open market sales reported on this line occurred at a weighted average price of $236.85 (range $236.84 to $236.87).